The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT). The authorisation paves the way for adult patients in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!